Table 3.
Multivariate analyses of significant factors for various endpoints in the 749 patients with NPC
| Variable | Local failure | Regional failure | Distant failure | Disease failure | Death (any cause) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| T stage (T2, T3, and T4 vs. T1) | 1.956 (1.371–2.790) | <0.001 | 1.243 (0.809–1.912) | 0.321 | 1.556 (1.282–1.888) | <0.001 | 1.589 (1.363–1.853) | <0.001 | 1.583 (1.328–1.886) | <0.001 |
| N stage (N1, N2, and N3 vs. N0) | 1.233 (0.833–1.723) | 0.218 | 1.416 (0.928–2.160) | 0.106 | 1.741 (1.485–2.041) | <0.001 | 1.617 (1.415–1.847) | <0.001 | 1.690 (1.455–1.964) | <0.001 |
| Age (>50 vs. ≤50 years) | 1.011 (0.490–2.086) | 0.976 | 1.005 (0.365–2.769) | 0.992 | 1.530 (1.037–2.256) | 0.032 | 1.896 (1.403–2.561) | <0.001 | 2.482 (1.770–3.482) | <0.001 |
| Sex (female vs. male) | 0.826 (0.378–1.802) | 0.631 | 0.797 (0.266–2.386) | 0.685 | 1.066 (0.689–1.649) | 0.776 | 1.017 (0.713–1.450) | 0.926 | 0.900 (0.587–1.379) | 0.627 |
| Histology (type II/III vs. type I) | 1.930E4 (0.000–6.656E258) | 0.974 | 2.104E4 (0.000–) | 0.981 | 2.313E4 (0.000–4.202E155) | 0.955 | 1.397 (0.194–10.043) | 0.739 | 1.037 (0.144–7.480) | 0.971 |
| Chemotherapy (CCRT, induction with CCRT, and CCRT with adjuvant vs. none) | 0.921 (0.705–1.202) | 0.544 | 0.920 (0.629–1.345) | 0.666 | 1.002 (0.870–1.155) | 0.973 | 0.947 (0.840–1.068) | 0.375 | 0.969 (0.847–1.108) | 0.644 |
HR hazard ratio, CI confidence interval, CCRT concurrent chemoradiotherapy